1.Salvage treatment of relapsed/refractory LCH.
Blood Research 2016;51(4):220-222
No abstract available.
Salvage Therapy*
2.Urologic Applications of Cryo-Immunology.
Abhinav SIDANA ; Ronald RODRIGUEZ
Korean Journal of Urology 2009;50(7):629-634
PURPOSE: Cryoablation is gaining acceptance as a primary treatment of localized metastatic urologic malignancies as well as a salvage therapy. Anecdotal clinical reports suggest that cryoablation can induce a systemic antitumor immune response, which has been confirmed in animal models also. MATERIALS AND METHODS: A review of the relevant literature was performed to suggest urologic applications of cryo-immunology. RESULTS: This article reviews the existing evidence regarding cryo-immunology and discusses the mechanisms for generation of an anti-tumor immune response. CONCLUSIONS: Our findings suggest combining cryoablation with other immunotherapeutic approaches to devise a cryo-immunotherapeutic strategy with potential to impact the progression of metastatic disease.
Cryosurgery
;
Immunotherapy
;
Kidney Neoplasms
;
Models, Animal
;
Prostatic Neoplasms
;
Salvage Therapy
3.A Case of Achieving Complete Remission with Stereotactic Body Radiation Therapy in Patients with Hepatocellular Carcinoma with Macrovascular Invasion after Repeated Transarerial Chemoembolization.
Sang Youn HWANG ; Seon Mi LEE ; Jong Woo IM ; Ki Jeong JEON ; Sang Bu AHN ; Eun Kyeong JI ; Jin Young PARK ; Cheol Won CHOI ; Gwang Mo YANG
Journal of Liver Cancer 2016;16(2):123-128
Transarterial chemoembolization (TACE) is the worldwide procedure performed for patients with various stage hepatoceullar carcinoma (HCC), but is not yet considered as curative treatment because of relatively high local recurrence rate. Moreover, many clinicians frequently experience treatment failure (incomplete necrosis or stage progression etc.) after repeated TACE, but no clear guidelines have been recommended about salvage treatment modalities for this situation. Recently, studies for combination of radiation therapy and TACE for HCC with TACE refractoriness have been tried and reported better therapeutic efficacy. Based on above suggestions, we herein offer our experience of a patient with macrovascular invasion developed after repeated TACE that achieve complete remission by stereotactic body radiation therapy. Further study, maybe regarding a combination of locoregional and systemic therapy, is necessary on how to manage HCC patients with TACE refractoriness.
Carcinoma, Hepatocellular*
;
Humans
;
Necrosis
;
Recurrence
;
Salvage Therapy
;
Treatment Failure
4.Is Intratympanic Dexamathasone Injection Effective for the Treatment of Idiopathic Sudden Sensorineural Hearing Loss?.
Kyu Ho LEE ; Sung Hoon RYU ; Hyung Min LEE ; Su Kyoung PARK ; Hyung Jong KIM ; Jiwon CHANG
Journal of Audiology & Otology 2015;19(3):154-158
BACKGROUND AND OBJECTIVES: The purpose of this study is to identify the effectiveness of intratympanic (IT) steroids when used as an initial therapy in sudden sensorineural hearing loss (SSNHL), and when it is used as a salvage therapy in a refractory SSNHL. SUBJECTS AND METHODS: This retrospective study included 122 patients with SSNHL. First, patients were divided into three groups according to the initial treatment; IT steroid, systemic steroid and combined (systemic and IT steroid) groups. Second, patients were divided into two groups according to the salvage treatment in a refractory SSNHL; IT steroid and the control (non IT group). Fifty eight patients who did not respond to initial therapy were included in the second analysis. Hearing was assessed immediately before the treatment and 2 weeks, 4 weeks and 3 months after the treatments. Hearing recovery was defined as an improvement of >15 dB and the final hearing of 25-45 dB in the audiogram. RESULTS: When we analyzed the hearing recovery in initial treatment, the comparison of audiogram among three groups did not result in significantly different outcomes. There were no differences in the recovery rate in 2 and 4 weeks throughout all the frequencies. Also, the analysis of the salvage treatment demonstrated that neither IT steroid group nor control group was significantly effective in treating the refractory SSNHL. CONCLUSIONS: The results suggest that initial treatment of SSNHL with IT steroid alone is as effective as systemic steroid alone or a combination therapy. Also, salvage IT steroids for refractory SSNHL did not have any additional beneficial effects.
Hearing
;
Hearing Loss, Sensorineural*
;
Humans
;
Retrospective Studies
;
Salvage Therapy
;
Steroids
5.A Case of Achieving Complete Remission with Combination of Sorafenib and Tegafur in Patients with Hepatocellular Carcinoma with Progression of Disease after Sorafenib Therapy.
Sang Youn HWANG ; Seon Mi LEE ; Jung Woo IM ; Ki Jeong JEON ; Sang Bu AHN ; Jin Young PARK ; Cheol Won CHOI ; Kwang Mo YANG
Journal of Liver Cancer 2017;17(1):88-93
Sorafenib is the only approved targeted agent as the first line systemic therapy for treatment of advanced hepatocellular carcinoma (HCC). However, the improvement of survival duration under 3 months is far from clinical satisfactory and most patients experience disease progression within 6 months after sorafenib therapy. Unfortunately, second line systemic therapy after treatment failure of sorafenib was not established and there were no clear guidelines for salvage treatment modalities. Recently, studies suggests that combination of sorafenib and single cytotoxic agent can be relatively effective and safe strategy that achieves promising rates of local and systemic control in advanced HCC patients. Based on above suggestions, we herein offer our experience of a case achieved complete remission by combination therapy of sorafenib and tegafur in the patient with progressed disease after sorafenib therapy.
Carcinoma, Hepatocellular*
;
Disease Progression
;
Humans
;
Salvage Therapy
;
Tegafur*
;
Treatment Failure
7.Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
Pasquale NISCOLA ; Carmen Di GRAZIA ; Carla MAZZONE ; Barbara TOLU ; Paolo DE FABRITIIS ; Emanuele ANGELUCCI
Blood Research 2019;54(4):288-290
No abstract available.
Azacitidine
;
Decitabine
;
Leukemia, Myeloid, Acute
;
Salvage Therapy
;
Myelodysplastic Syndromes
8.A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer.
Bong Gun SEO ; Sung Yong OH ; Dong Mee LEE ; Hyun Seung YOO ; Suee LEE ; Seong Geun KIM ; Sung Hyun KIM ; Hyuk Chan KWON ; Hyo Jin KIM
Cancer Research and Treatment 2007;39(1):6-9
PURPOSE: To evaluate the therapeutic activity and safety of paclitaxel and cisplatin combination chemotherapy in patients with advanced or metastatic gastric cancers that are unresponsive to primary chemotherapy. MATERIALS AND METHODS: Advanced or metastatic gastric cancer patients unresponsive to first line chemotherapy were entered into this trial. The treatment regimen consisted of paclitaxel, 175 mg/m(2) by 3-hour infusion on day 1, and cisplatin, 60 mg/m(2) by 1 hour infusion on day 1, with the treatment repeated every 3 weeks. RESULTS: 37 patients were entered in this study, with 32 fully evaluable for response. 4 (13%), 13 (40%) and 15 (47%) patients achieved a partial response, stable disease and progressed, respectively. The median time to progression was 4.0 months (95% CI: 2.0~6.0 months), and the median overall survival was 12.6 months (95% CI: 5.5~19.7 months), with a 1-year survival rate of 54%. Of a total of 135 cycles of chemotherapy, grades 3 and 4 hematological toxicities were neutropenia (14%) and anemia (3%). Grade > or =2 neuropathy was observed in 6 patients (17%). CONCLUSION: The combination of paclitaxel and cisplatin is an effective and tolerable salvage treatment modality for advanced gastric cancer.
Anemia
;
Cisplatin*
;
Drug Therapy
;
Drug Therapy, Combination
;
Humans
;
Neutropenia
;
Paclitaxel*
;
Salvage Therapy*
;
Stomach Neoplasms*
;
Survival Rate
9.Salvage therapy for severe aplastic anemia after allogenenic hematopoietic cell transplant.
Jing ZHANG ; Xingxin LI ; Yingqi SHAO ; Jun SHI ; Meili GE ; Zhendong HUANG ; Neng NIE ; Jinbo HUANG ; Yizhou ZHENG
Chinese Journal of Hematology 2014;35(5):414-418
OBJECTIVETo probe a practical salvage strategy for relapse or failure patients with severe aplastic anemia (SAA) after allogenenic hematopoietic cell transplant (allo-HSCT).
METHODSThe clinical characteristics and initial treatments of allo-HSCT, and the responses of a novel salvage therapy of cyclosporine alternately combined with levamisole (CsA & LMS regimen) plus danazol (DNZ) in 2 patients were reviewed and evaluated.
RESULTS(1) Patient 1 achieved partial response (PR) at 3 months and complete response (CR) at 6 months after CsA & LMS regimen, respectively; Patient 2 also achieved PR 3 months and nearly CR at 6 months after the salvage therapy, respectively. (2) Increased numbers of T regulatory cells and colony forming unit-erythroid, burst-forming unit-erythroid, colony forming unit-granulocytes/macrophages after CsA & LMS regimen in both patients were observed.
CONCLUSIONThis was the first report of successful salvage by a novel strategy of CsA & LMS regimen for relapse or failure patients with SAA after allo-HSCT.
Anemia, Aplastic ; therapy ; Cyclosporine ; therapeutic use ; Hematopoietic Stem Cell Transplantation ; Humans ; Recurrence ; Salvage Therapy
10.Successful Response of Oral Etoposide for Refractory Neuroblastoma.
Young Myoung KIM ; Bong Jin KIM ; Jung Pyo KIM ; Young Ho LEE
Korean Journal of Pediatric Hematology-Oncology 2003;10(1):115-120
Intensive chemotherapy with or without stem cell rescue has become widely accepted for treatment of neuroblastoma because increased dose-intensity correlates with improved response rates. For neuroblastoma that is resistant to intensive chemotherapy, further use of high-dose therapy is unlikely to be beneficial. For disease that recurs after myeloablative consolidation, high-dose salvage therapy may not be feasible because of poor bone marrow reserve and may not be justified in view of its morbidity in the absence of a realistic chance for cure. One treatment option in these difficult clinical settings is chronic oral administration of low-dose etoposide. However, there has been a few clinical reports for the experience of oral etoposide for refractory neuroblastoma. We now present 2 cases of successful response of oral etoposide for refractory neuroblastoma.
Administration, Oral
;
Bone Marrow
;
Drug Therapy
;
Etoposide*
;
Neuroblastoma*
;
Salvage Therapy
;
Stem Cells